Literature DB >> 1584897

The Revised Toronto Alexithymia Scale: some reliability, validity, and normative data.

G J Taylor1, R M Bagby, J D Parker.   

Abstract

Addressing certain problems with the compositional structure of the self-report Toronto Alexithymia Scale, this paper reports the development of a revised version of the scale as well as results from a preliminary series of studies evaluating its reliability and validity. The Revised Toronto Alexithymia Scale (TAS-R) demonstrated good internal consistency and a stable and replicable two-factor structure that is congruent with the two major dimensions of the alexithymia construct. Evidence of convergent and discriminant validity for the TAS-R was provided by correlations with measures of other constructs. Criterion validity was demonstrated by the ability of TAS-R scores to discriminate between behavioral medicine outpatients designated alexithymic and those designated non-alexithymic on the basis of clinical interview ratings. Normative data are provided for university student, normal adult, and psychiatric outpatient populations.

Entities:  

Mesh:

Year:  1992        PMID: 1584897     DOI: 10.1159/000288571

Source DB:  PubMed          Journal:  Psychother Psychosom        ISSN: 0033-3190            Impact factor:   17.659


  35 in total

1.  The relationship between alexithymia and maladaptive perfectionism in eating disorders: a mediation moderation analysis methodology.

Authors:  S Marsero; G M Ruggiero; S Scarone; S Bertelli; S Sassaroli
Journal:  Eat Weight Disord       Date:  2011-09       Impact factor: 4.652

2.  Neuropsychological correlates of normal variation in emotional response to visual stimuli.

Authors:  Robert G Robinson; Sergio Paradiso; Romina Mizrahi; Jess G Fiedorowicz; Dimitrios E Kouzoukas; David J Moser
Journal:  J Nerv Ment Dis       Date:  2007-02       Impact factor: 2.254

3.  Alexithymia and 7.5-year incidence of compensated low back pain in 1207 urban public transit operators.

Authors:  Wolf E Mehling; Niklas Krause
Journal:  J Psychosom Res       Date:  2007-06       Impact factor: 3.006

4.  Aging and alexithymia: association with reduced right rostral cingulate volume.

Authors:  Sergio Paradiso; Jatin G Vaidya; Laurie M McCormick; Andria Jones; Robert G Robinson
Journal:  Am J Geriatr Psychiatry       Date:  2008-08-12       Impact factor: 4.105

5.  Work-related and psychological determinants of multisite musculoskeletal pain.

Authors:  Eleni Solidaki; Leda Chatzi; Panos Bitsios; Irini Markatzi; Estel Plana; Francesc Castro; Keith Palmer; David Coggon; Manolis Kogevinas
Journal:  Scand J Work Environ Health       Date:  2009-12-11       Impact factor: 5.024

6.  Alexithymia in Amyotrophic Lateral Sclerosis and Its Neural Correlates.

Authors:  Soumia Benbrika; Franck Doidy; Laurence Carluer; Audrey Mondou; Marie-Sonia Buhour; Francis Eustache; Fausto Viader; Béatrice Desgranges
Journal:  Front Neurol       Date:  2018-07-24       Impact factor: 4.003

7.  Somatisation and alexithymia in patients with high use of medical care and medically unexplained symptoms.

Authors:  Norman H Rasmussen; David C Agerter; Robert C Colligan; Macaran A Baird; Charles E Yunghans; Stephen S Cha
Journal:  Ment Health Fam Med       Date:  2008-09

8.  The predictive value of the Toronto Alexithymia Scale among patients with asthma.

Authors:  Jonathan M Feldman; Paul M Lehrer; Stuart M Hochron
Journal:  J Psychosom Res       Date:  2002-12       Impact factor: 3.006

9.  Measuring Alexithymia via Trait Approach-I: A Alexithymia Scale Item Selection and Formation of Factor Structure.

Authors:  Arkun Tatar; Gaye Saltukoğlu; Seda Alioğlu; Sümeyye Çimen; Hülya Güven; Çağla Ebru Ay
Journal:  Noro Psikiyatr Ars       Date:  2016-09-01       Impact factor: 1.339

10.  Altered Insula Activity during Visceral Interoception in Weight-Restored Patients with Anorexia Nervosa.

Authors:  Kara L Kerr; Scott E Moseman; Jason A Avery; Jerzy Bodurka; Nancy L Zucker; W Kyle Simmons
Journal:  Neuropsychopharmacology       Date:  2015-06-18       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.